Loading...
Suraksha Diagnostic IPO Details, Financials, Valuation & Peers
By IPOBase •Last Updated on
Explore Suraksha Diagnostic IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Status
Listed
Biding Dates
29 Nov - 03 Dec 2024
Price Range
₹420 - ₹441
Min Investment
₹14,994
Lot Size
34 shares
Issue Size
₹846.25 crore
Listed Price
₹438-0.68%
Overview
Suraksha Diagnostic Limited is a provider of integrated diagnostic and medical consultation services, offering a wide range of pathology, radiology, and specialized healthcare services. With a robust operational network across West Bengal, Bihar, Assam, and Meghalaya, the company is dedicated to delivering quality healthcare solutions under a single roof. As of June 30, 2024, its network includes a central reference laboratory, 8 satellite laboratories, 49 diagnostic centers, and 166 franchised sample collection centers. Suraksha Diagnostic also houses 126 polyclinic chambers hosting over 750 specialized doctors, reinforcing its position as a trusted healthcare provider in Eastern India. The company operates on a hub-and-spoke model, enabling efficient sample collection and testing through its centralized laboratories. Its offerings span over 2,300 tests across routine and specialized pathology and radiology, catering to a diverse range of healthcare needs. Suraksha Diagnostic serves individual patients (B2C) while prioritizing convenience through walk-ins, home sample collection, and online consultations.
Key Points:
- Extensive Network
- Central Reference Laboratory: Accredited by the College of American Pathologists.
- 8 Satellite Laboratories: Co-located with diagnostic centers.
- 215 Customer Touchpoints: Comprising 49 diagnostic centers and 166 sample collection centers.
- Comprehensive Services
- Offers 788 routine pathology tests and 664 specialized pathology tests.
- Provides 766 basic/intermediate radiology tests and 119 advanced radiology tests, including CT and MRI scans.
- Additional services include vaccinations and customized health packages.
- Polyclinic Services: Operates 126 polyclinic chambers offering consultations with 750+ specialized doctors across multiple disciplines, ensuring integrated patient care.
- Revenue Mix
- Majority revenue from B2C segment (~93% in Fiscal 2024).
- Core geography (Kolkata and West Bengal) contributes ~95% of operational revenue.
- Growth Metrics
- Conducted approximately 5.98 million tests for 1.14 million patients in Fiscal 2024.
- Established market share of 1.15%–1.30% in Eastern India’s diagnostics market.
Objects of the Issue
- Carry out the Offer for Sale of up to 19,189,330 Equity Shares of face value ₹ 2
- Achieve the benefits of listing the Equity Shares on the Stock Exchanges.
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 29 Nov - 03 Dec 2024 |
| IPO Price Band | ₹420 - ₹441 per share |
| Fresh Issue | NIL |
| Offer For Sale | 19,189,330 shares |
| Total IPO Size | ₹846.25 crore |
| Face Value | ₹2 |
| Listing On | BSE, NSE |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 29 Nov 2024 |
| IPO Closing Date | 03 Dec 2024 |
| Basis Of Allotment | 04 Dec 2024 |
| Refunds | 05 Dec 2024 |
| Demat Transfer | 05 Dec 2024 |
| IPO Listing Date | 06 Dec 2024 |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | Jun 2024 |
|---|---|---|---|---|
| Total Income | 225.77 | 193.69 | 222.26 | 61.85 |
| Total Expenses | 197.76 | 186.94 | 190.03 | 51.34 |
| Net Profit/Loss | 20.82 | 6.07 | 23.13 | 7.67 |
| NPM (*) | 9.33 | 3.19 | 10.57 | 12.62 |
| Total Assets | 275.96 | 281.20 | 300.21 | 314.20 |
| Total Liabilities | 130.13 | 125.73 | 121.06 | 127.58 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Valuation
Uncover significant valuation metrics such as EPS (Earnings Per Share), ROE (Return on Equity), ROCE (Return on Capital Employed), D/E Ratio (Debt-to-Equity Ratio), Current Ratio, and EBITDA Margin. These key indicators offer insights into the company's financial standing and performance, aiding in informed investment decisions.
| Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | Jun 2024 |
|---|---|---|---|---|
| EPS | 3.91 | 1.22 | 4.43 | 1.49 |
| ROE (%) | 15.38 | 4.32 | 14.09 | 4.33 |
| ROCE (%) | 23.11 | 9.05 | 21.46 | 6.32 |
| D/E Ratio | 0.37 | 0.27 | 0.20 | 0.16 |
| Current Ratio | 1.64 | 1.77 | 1.84 | 1.77 |
| EBITDA MARGIN (%) | 29.24 | 24.97 | 33.66 | 35.77 |
* Compiled from DRHP/RHP for valuation purposes.
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | Revenue | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|---|
| Suraksha Diagnostic Limited | 218.71 | 99.55 | 4.43 | 14.09 | 33.66 |
| Dr Lal PathLabs | 2,226.64 | 77.08 | 42.98 | 20.35 | 221.53 |
| Metropolis Healthcare | 1,207.71 | 89.61 | 24.87 | 12.26 | 213.98 |
| Thyrocare | 572.39 | 65.52 | 13.40 | 13.34 | 99.48 |
| Vijaya Diagnostic | 547.81 | 86.40 | 11.59 | 19.77 | 64.21 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
IPO Reservation
| Investor Type | Shares Offered |
|---|---|
| Qualified Institutional Buyer (QIB) | Not less than 50% |
| Non-Institutional Investor (NII/HNI) | Not more than 15% |
| Retail Individual Investor (RII) | Not more than 35% |
Subscription Data from NSE and BSE
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 1.74 |
| Non-Institutional Investor (NII/HNI) | 1.4 |
| Retail Individual Investor (RII) | 0.94 |
| Total | 1.27 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
IPO Registrar
KFin Technologies Limited
Phone: +91 40 6716 2222/ 18003094001
Email: einward.ris@kfintech.com
Website: www.kfintech.com
Company Promoters
- DR. SOMNATH CHATTERJEE
- RITU MITTAL
- SATISH KUMAR VERMA
Lead Managers
- ICICI SECURITIES LIMITED
- NUVAMA WEALTH MANAGEMENT LIMITED
- SBI CAPITAL MARKETS LIMITED
Company Address
Suraksha Diagnostic Limited
Plot No. DG-12/1, Action Area 1D, Premises No. 02- 0327, New Town, Rajarhat, Kolkata 700 156 West Bengal, India
Phone: +91 33 66059750
Email: investors@surakshanet.com
Website: www.surakshanet.com
FAQs
- What is the issue size of the Suraksha Diagnostic IPO?The Suraksha Diagnostic IPO has an issue size of ₹846.25 crore. This includes a fresh issue of NIL and an offer for sale (OFS) of 19,189,330 shares.
- What is the price band of the Suraksha Diagnostic IPO?The price band for the Suraksha Diagnostic IPO is ₹420 - ₹441 per share.
- What are the bidding dates for the Suraksha Diagnostic IPO?The Suraksha Diagnostic IPO will open for bidding on 29 Nov 2024 and close on 03 Dec 2024.
- What is the allotment date for the Suraksha Diagnostic IPO?The allotment date for the Suraksha Diagnostic IPO is 04 Dec 2024.
- What is the minimum lot size and investment required for the Suraksha Diagnostic IPO?The minimum lot size for the Suraksha Diagnostic IPO is 34 shares and the minimum investment required is ₹14,994.
- What is the listing date for the Suraksha Diagnostic IPO?The listing date for the Suraksha Diagnostic IPO is 06 Dec 2024.
- What is the Suraksha Diagnostic IPO grey market premium?The grey market premium (GMP) for the Suraksha Diagnostic IPO is currently at ₹15, with an expected listing gain of approximately 3.4%. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.